share_log

Ginkgo Bioworks | DEFA14A: Others

Ginkgo Bioworks | DEFA14A: Others

Ginkgo Bioworks | DEFA14A:其他
美股sec公告 ·  04/29 16:04
Moomoo AI 已提取核心訊息
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has announced the nomination of Myrtle Potter and Ross Fubini as independent directors for election at the company's annual meeting on June 13, 2024. The announcement comes as current Board Chair Marijn Dekkers and Nominating and Corporate Governance Committee Chair Reshma Kewalramani are set to retire and not seek reelection. CEO Jason Kelly expressed gratitude for the outgoing members' contributions and enthusiasm for the incoming nominees' expertise. Potter has a significant background in pharmaceutical R&D and corporate leadership, including roles at Sumitomo Pharma America and Genentech. Fubini brings experience from the venture capital sector, having founded XYZ Venture Capital and supported numerous companies. The nominations are part of Ginkgo Bioworks' ongoing efforts to enhance its board's capabilities in cell programming and biosecurity. The company is a leader in providing services across various markets, including food, agriculture, pharmaceuticals, and industrial chemicals. The press release also contains forward-looking statements regarding the potential election of the new directors and the company's future plans.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has announced the nomination of Myrtle Potter and Ross Fubini as independent directors for election at the company's annual meeting on June 13, 2024. The announcement comes as current Board Chair Marijn Dekkers and Nominating and Corporate Governance Committee Chair Reshma Kewalramani are set to retire and not seek reelection. CEO Jason Kelly expressed gratitude for the outgoing members' contributions and enthusiasm for the incoming nominees' expertise. Potter has a significant background in pharmaceutical R&D and corporate leadership, including roles at Sumitomo Pharma America and Genentech. Fubini brings experience from the venture capital sector, having founded XYZ Venture Capital and supported numerous companies. The nominations are part of Ginkgo Bioworks' ongoing efforts to enhance its board's capabilities in cell programming and biosecurity. The company is a leader in providing services across various markets, including food, agriculture, pharmaceuticals, and industrial chemicals. The press release also contains forward-looking statements regarding the potential election of the new directors and the company's future plans.
Ginkgo Bioworks Holdings, Inc.(紐約證券交易所代碼:DNA)宣佈提名默特爾·波特和羅斯·富比尼爲獨立董事,將在2024年6月13日的公司年會上進行選舉。該公告發布之際,現任董事會主席瑪麗恩·德克斯和提名與公司治理委員會主席雷什瑪·凱瓦爾拉馬尼即將退休,不尋求連任。首席執行官傑森·凱利對離任成員的貢獻表示感謝,並對新候選人的專業知識表示熱情。Potter 在藥物研發和企業領導方面擁有豐富的背景,包括在美國住友製藥和基因泰克任職。Fubini帶來了風險投資領域的經驗,他創立了XYZ風險資本並支持了許多公司。這些提名是Ginkgo Bioworks爲提高其董事會在細胞編程和生物安全方面的能力所做的持續努力的一部分。該公司在爲食品、農業、藥品和工業化學品等各個市場提供服務方面處於領先地位。新聞稿還包含有關新董事可能當選和公司未來計劃的前瞻性陳述。
Ginkgo Bioworks Holdings, Inc.(紐約證券交易所代碼:DNA)宣佈提名默特爾·波特和羅斯·富比尼爲獨立董事,將在2024年6月13日的公司年會上進行選舉。該公告發布之際,現任董事會主席瑪麗恩·德克斯和提名與公司治理委員會主席雷什瑪·凱瓦爾拉馬尼即將退休,不尋求連任。首席執行官傑森·凱利對離任成員的貢獻表示感謝,並對新候選人的專業知識表示熱情。Potter 在藥物研發和企業領導方面擁有豐富的背景,包括在美國住友製藥和基因泰克任職。Fubini帶來了風險投資領域的經驗,他創立了XYZ風險資本並支持了許多公司。這些提名是Ginkgo Bioworks爲提高其董事會在細胞編程和生物安全方面的能力所做的持續努力的一部分。該公司在爲食品、農業、藥品和工業化學品等各個市場提供服務方面處於領先地位。新聞稿還包含有關新董事可能當選和公司未來計劃的前瞻性陳述。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息